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BACKGROUND: Our recent study observed that the expression of ubiquitin D (UBD), a member of ubiquitin-like modifier family, was
upregulated in colon cancer parenchymal cells. The present study further investigated the clinical signicance of UBD in colon cancer.
METHODS: Using quantitative PCR, tissue microarray (TMA), western blot analysis and immunohistochemical stain, we evaluated UBD
mRNA and protein levels in tumour tissues from patients with colon cancer at different stages and in paired adjacent normal
epithelium.
RESULTS: Immunohistochemical detection of UBD on a TMA containing 203 paired specimens showed that increased cytoplasmic
UBD was signicantly associated with depth of cancer invasion, lymph node metastasis, distant metastasis, tumour histologic grade,
advanced clinical stage and Ki-67 proliferative index. Patients with UBD-positive tumours had a significantly higher disease recurrence
rate and poorer survival than patients with UBD-negative tumours after the radical surgery. Stratification analysis according to tumour
stage revealed UBD as an independent predictor for tumour recurrence in patients with stage II and III tumours.
CONCLUSION: UBD may contribute to the progression of colon carcinogenesis and function as a novel prognostic indicator of
forecasting recurrence of stage II and III patients after curative operations.
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Colon cancer is a major cause of cancer morbidity and mortality
and is the third most fatal malignancy worldwide (Jemal et al,
2009). In China and other economically transitioning countries,
colon cancer incidence rates have increased over the last 20 years,
most likely due to changes in the environment and individual
life style and nutritional habits (Zhang et al, 2009). In certain
high prevalence regions, colon cancer mortality has become the
second leading cause of cancer death (Jiang et al, 2009). Surgical
resection is the most widely used treatment for colon cancer.
tumour recurrence, the main factor for the failure of colon cancer
therapy following radical surgery, negatively impacts patient
quality of life and frequently results in patient mortality. At
present, risk assessment for colon cancer recurrence is mainly
based on tumour node metastasis staging (O’Connell et al, 2004).
However, clinical outcomes are quite variable, even among
patients diagnosed at the same tumour stage (Galandiuk et al,
1992). Therefore, there is an urgent need to discover and utilize
novel factors for predicting tumour recurrence at the time of
operation that could assist in implementing individualized,
directed therapeutic regimens.
The complicated process of tumour recurrence involves a
number of biological changes, including deregulated expression
of several oncogenes and tumour suppressor genes within tumour
cell subpopulations (Grady and Carethers, 2008). Although several
molecular biomarkers, including K-ras, p53 and DPC4, have
been evaluated as candidate prognostic indicators in colon cancer
(Paul-Samojedny et al, 2005; Duffy et al, 2007), none of these
markers has been widely adopted due to conicting literature
reports. The protein Ki-67 (also known as MKI67) is a cellular
marker for proliferation that is detectable within the cell nucleus
during all active phases of the cell cycle (G1, S, G2 and mitosis),
but is not expressed in resting cells (Scholzen and Gerdes, 2000).
Although Ki-67 expression is widely used as a tumour proliferative
index and has been associated with colon cancer treatment
response and prognosis (Salminen et al, 2005; Fluge et al, 2009),
its clinical utility in predicting disease outcomes remains a topic
of investigation.
We recently reported the use of laser capture microdissection
and complementary DNA microarrays to explore gene expression
profiles in colon cancer parenchymal cells (Fan et al, 2008). Using
these techniques, we showed upregulation of ubiquitin D (UBD,
also known as FAT10) levels in cancer cells (signal log ratio 1.9)
when compared with normal colon epithelial tissue (paper in
preparation). UBD was first discovered in reticuloendothelial
tissues and mucosal-associated lymphoid immunological systems
as one of the genes at the human major histocompatibility complex
class I locus on chromosome 6 (Fan et al, 1996; Bates et al, 1997;
Ebstein et al, 2009). The UBD gene encodes an 18kDa protein
containing an N- and C-terminus with 29 and 36% identity with
ubiquitin, respectively (Fan et al, 1996). Of the ubiquitin-like
proteins that have been identified, UBD is the only one of
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sthat conjugate to target proteins by a free diglycine motif at the
C-terminus and directly guides noncovalently bound proteins to
proteasomal degradation (Hipp et al, 2005; Kalveram et al, 2008;
Schmidtke et al, 2009).
UBD also has important roles in cell mitosis, chromosome
instability, apoptosis and immune response (Raasi et al,2 0 0 1 ;
Canaan et al, 2006; Lim et al, 2006; Ren et al, 2006). UBD deregulation
may induce abnormal alterations in apoptosis, cell division or
chromosome instability, which are associated with neoplastic change
(Sarasin, 2003; Adler et al, 2009). tumour UBD expression shows
some tissue specificity, with transcriptional upregulation observed in
liver, uterine cervix, ovarian, pancreatic, gastric and small intestine
adenocarcinomas, but not in thyroid, prostate or kidney cancers (Lee
et al, 2003; Lukasiak et al, 2008a). In hepatic cancer cells, increased
expression of UBD was associated with Proliferating Cell Nuclear
Antigen, a cell proliferation marker, and reported to provide a growth
advantage over cells without UBD expression (Oliva et al, 2008). High
UBD expression also promoted hepatocellular carcinoma develop-
ment in a mouse model and formation of Mallory–Denk bodies,
which are preneoplastic changes in chronic liver disease (Oliva et al,
2008, 2009). Overexpression of UBD in gastric cancer has been
correlated with metastasis and tumour staging, and both UBD mRNA
and protein levels were identified as independent prognostic factors
for this disease (Ji et al, 2009). Increased UBD has also been positively
correlated with mutant p53 expression, which may activate UBD
expression and indirectly facilitate gastric cancer progression (Zhang
et al,2 0 0 6 ;J iet al, 2009). Interferon-g and tumour necrosis factor-a
act synergistically to induce the UBD promoter through an interferon
sequence resposive element (Oliva et al, 2010). Collectively, these data
indicate that UBD may be a marker for precancerous lesions and may
promote cancer progression.
The clinical significance and prognostic value of UBD expres-
sion in colon cancer has not been reported. The present study
evaluated UBD expression in fresh frozen colon cancer specimens
and paired normal epithelium and cancer samples on a tissue
microarray (TMA) to establish whether UBD expression was
associated with the clinicopathological features of colon cancer,
risk of disease recurrence or patient survival.
MATERIALS AND METHODS
Tissue specimens
A total of 203 patients with colon cancer permitted operation by the
same surgical team with the General Surgery Department of
Shanghai Jiao Tong University Affiliated First People’s Hospital
from 2001 to 2003. No patients received either chemotherapy or
radiotherapy before surgery. There were 86 male and 117 female
patients, with a median age of 68 years (range, 22–95 years) at the
time of operation. The tumour grade and stage classification were
made as previously described (O’Connell et al, 2004; Chen et al,
2009). Patients with stage III and IV disease underwent standard
chemotherapeutic protocols with 5-fluorouracil following surgery as
per The National Comprehensive Cancer Network Practice Guide-
lines for Colorectal Cancer (Benson et al, 2000). Depending on the
disease status, one of the three different therapy plans was used on
each patient. Although most of the patients began to receive
chemotherapy 2 weeks after the surgery, some patients received the
chemotherapy 3–4 weeks after the surgery on the basis of their
recovery. Supplementary Table S1 describes the post-operative
chemotherapy plan for patients with stage III or IV colon cancer.
Detailed patient demographic information is presented in
Table 1. Vascular invasion was defined as vessel wall occlusion
or destruction, with a surrounding fibroinflammatory reaction
(Chen et al, 2009). The median patient follow-up time was 61
months after surgery (range, 9–89 months). All patients provided
informed consent according to a protocol approved by the
Institutional Review Board of Shanghai First People’s Hospital.
RNA extraction, quantitative real-time PCR and reverse
transcription PCR
Total RNA was extracted from frozen primary tumour and
adjacent normal mucosa of colon cancer specimens according to
the manufacturer’s instructions (Qiagen, Hilden, Germany), and
then 1mg RNA was reverse transcribed into complementary DNA
using an A3500 RT-PCR System (Promega Corporation, Madison,
WI, USA). The primers used for RT-PCR were: UBD, sense 50-CA
TCCACCTTACCCTGAA-30 and antisense 50-ATACCCGTCTTA
GTCTCG-30 (156bp); and b-actin, sense 50-CGGGAAATGTGCGTG
AC-30 and antisense 50-TGGAAGGTGGACAGCGAGG-30 (434bp).
A1ml aliquot of complementary DNA was amplified using specific
primers and GoTaq Green Master Mix M7122 (Promega) in a MJ
PTC-100 programmable thermal controller (Bio-Rad, Hercules,
CA, USA). The cycling conditions were as follows: 951C for 2min,
and then 30 cycles of 951C for 30s, 551C for 30s and 721C for 45s,
with a final extension at 721C for 5min. PCR products were
separated on 1.5% agarose gels and then visualized using an
ultraviolet imaging system (FuRi Co., ShangHai, China).
To further confirm UBD gene expression in colon tumours,
relative UBD mRNA levels were assessed in 30 randomly selected,
paired normal mucosa and colon cancer tissues using an ABI Prism
7500 quantitative real-time PCR (qPCR) system (Applied Biosys-
tems, Foster City, CA, USA) and the IQTM SYBR Green Supermix
Kit (Bio-Rad) according to manufacturer’s instructions and using
the thermal cycling conditions described above. The primers for
qPCR were: UBD, sense 50-TTGATGCCAACCCATATGACAG-30 and
antisense 50-ATACCCGTCTTAGTCTCG-30; and glyceraldehyde
3-phosphate dehydrogenase, sense 50-TGACTTCAACAGCGACACC
CA-30 and antisense 50-CACCCTGTTGCTGTAGCCAAA-30.E a c h
reaction was repeated at least three times, and then the mean UBD
mRNA level for each tumour was compared with the level its
matched, non-tumourous tissue. The fold change (2-
DDCt) in UBD
expression in each paired sample was calculated using the
formulas: UBD
DCt¼(Avg.UBD_Ct Avg.GAPDH_Ct), UBD
DDCt¼
(UBD
DCt_tumour UBD
DCt_non-tumour).
Western blot
Total protein was extracted from frozen colon tumour and adjacent
normal tissue samples using an ice-cold Radio Immunoprecipitation
Assay lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate and 0.1% sodium dodecyl sulphate). Protein
concentrations were measured using a BCA protein assay kit
(Beyotime Biotechnology Co., Jiangsu, China). Equivalent amounts
of protein were separated on 12% sodium dodecyl sulphate–
polyacrylamide gels and then transferred onto polyvinylidene
difluoride membranes. The membranes were blocked in 5% fat-
free milk with 0.1% Tween 20 for 1h at room temperature, followed
by incubation with either the UBD primary mouse polyclonal
antibody (1:500, H00010537-B01, Abnova, Taipei, China) or b-actin
antibody (1:1000, Cell Signaling Technology, Beverly, MA, USA)
overnight at 41C. After washing with TBST buffer (10mM Tris
pH 8.0, 150mM NaCl, 0.1% Tween-20), blots were incubated with a
goat-anti-mouse immunoglobulin G–horseradish peroxidase
conjugate secondary antibody (1:4000, Abnova) for 40min, and
then bound antibodies were detected using enhanced chemilumi-
nescence (Pierce Biotechnology, Rockford, IL, USA) and exposure to
X-ray film. The abundance of each protein was determined and
normalized against b-actin expression.
TMA construction
For TMA construction, formalin-fixed, paraffin-embedded samples
containing primary tumours and paired normal mucosa, among
them 66 specimens of paired metastatic lymph nodes, were
retrieved from archives of the Department of Pathology of our
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sHospital. Representative areas of tissue were established by
microscopic review of H&E stained slides and 2.0mm diameter
cores were punched from the paraffin blocks. Two cores from
each of primary cancer and normal tissues at a distance of at least
2cm from the tumour were arrayed. TMAs were created using a
Tissue Microarrayer (Beecher Instruments, Sun Prairie, WI, USA).
All specimens were examined by at least two pathologists to prevent
bias. Tumour and normal mucosa morphology on the arrays were
validated as having high accordance with that of the whole archived
section.
Immunohistochemistry
UBD and Ki-67 expression were detected on the TMAs following
citrate buffer (pH 6.0) antigen retrieval using standard methodology
and a primary antibody against UBD (1:200, Abnova) or Ki-67
(1:50, Dako Cytomation, Copenhagen, Denmark). Tissue sections
were counterstained with Mayer’s hematoxylin. Positive staining
was scored by two independent investigators without the knowledge
of patient outcomes (double-blinded) according to the staining area
and intensity as described by (Bachmann et al,2 0 0 8 ) .S t a i n i n g
intensity was graded as follows: 0, no staining; 1þ,m i l ds t a i n i n g ;
2þ,m o d e r a t es t a i n i n g ;a n d3þ, intense staining. The staining area
was scored using the following scale: 0, no staining of cells; 1þ,
o10% of tissue stained positive; 2þ, 10–50% stained positive; and
3þ, 450% stained positive. The sum of staining score (intensity þ
extension) index was designated as follows: 0–2, negative expres-
sion; 3–4, weak expression; and 5–6, strong expression. Analysis of
Ki-67 index was on the basis of the percentage of nuclei stained
positive for Ki-67. We selected 10% positively staining nuclei as the
cutoff point dividing the negative group (p10% cells with positive
nuclei) and the positive group (410% cells with positive nuclei)
(Hashimoto et al, 2006). When discrepancy in an assessment was
encountered, the slides were re-examined by both pathologists
under a multi-head microscope to obtain an agreement.
Statistical analysis
For continuous variables, data are expressed as the median
and inter-quartile range and compared using the Mann–Whitney
Table 1 Association between clinicopathological features and UBD or Ki-67 protein expression
UBD expression Ki-67 index
Negative (n¼68) Weak (n¼71) Strong (n¼64) P Negative (n¼43) Positive (n¼160) P
Age (mean, range) 69.5 (54.0, 74.0) 66.0 (58.0, 75.0) 71.0 (57.5, 78.0) 0.208 71.0 (62.0, 78.0) 67.0 (56.0, 75.0) 0.132
Gender (n, %)
Male 34 (50.0%) 28 (39.4%) 24 (37.5%) 0.289 18 (41.9%) 68 (42.5%) 1.000
Female 34 (50.0%) 43 (60.6%) 40 (62.5%) 25 (58.1%) 92 (57.5%)
Location (n, %)
Right 29 (42.6%) 25 (35.2%) 30 (46.9%) 0.594 14 (32.6%) 70 (43.8%) 0.139
Transverse 6 (8.8%) 6 (8.5%) 7 (10.9%) 7 (16.3%) 12 (7.5%)
Left 33 (48.5%) 40 (56.3%) 27 (42.2%) 22 (51.2%) 78 (48.8%)
T Stage (n, %)
T1 3 (4.4%) 2 (2.8%) 3 (4.7%) 0.027* 3 (7.0%) 5 (3.1%) o0.001*
T2 15 (22.1%) 6 (8.5%) 2 (3.1%) 15 (34.9%) 8 (5.0%)
T3 20 (29.4%) 27 (38.0%) 29 (45.3%) 11 (25.6%) 65 (40.6%)
T4 30 (44.1%) 36 (50.7%) 30 (46.9%) 14 (32.6%) 82 (51.3%)
N stage (n, %)
N0 43 (63.2%) 37 (52.1%) 28 (43.8%) 0.021* 27 (62.8%) 81 (50.6%) 0.170
N1 21 (30.9%) 18 (25.4%) 22 (34.4%) 8 (18.6%) 53 (33.1%)
N2 4 (5.9%) 16 (22.5%) 14 (21.9%) 8 (18.6%) 26 (16.3%)
M stage (n, %)
M0 67 (98.5%) 62 (87.3%) 56 (87.5%) 0.018* 41 (95.3%) 144 (90.0%) 0.374
M1 1 (1.5%) 9 (12.7%) 8 (12.5%) 2 (4.7%) 16 (10.0%)
AJCC stage (n, %)
I 14 (20.6%) 7 (9.9%) 3 (4.7%) 0.019* 15 (34.9%) 9 (5.6%) o0.001*
II 28 (41.2%) 28 (39.4%) 25 (39.1%) 12 (27.9%) 69 (43.1%)
III 25 (36.8%) 27 (38.0%) 28 (43.8%) 14 (32.6%) 66 (41.3%)
IV 1 (1.5%) 9 (12.7%) 8 (12.5%) 2 (4.7%) 16 (10.0%)
Differentiation (n, %)
High 99 (48.8%) 46 (56.8%) 53 (43.4%) o0.001* 26 (60.5%) 73 (45.6%) 0.138
Moderate 74 (36.5%) 21 (25.9%) 53 (43.4%) 14 (32.6%) 60 (37.5%)
Low 30 (14.8%) 14 (17.3%) 16 (13.1%) 3 (7.0%) 27 (16.9%)
Vascular invasion (n, %)
Yes 3 (4.4%) 5 (7.0%) 6 (9.4%) 0.575 1 (2.3%) 13 (8.1%) 0.309
No 65 (95.6%) 66 (93.0%) 58 (90.6%) 42 (97.7%) 147 (91.9%)
Ki-67 index (n, %)
Negative 24 (35.3%) 11 (15.5%) 8 (12.5%) 0.003*
Positive 44 (64.7%) 60 (84.5%) 56 (87.5%)
Abbreviations: AJCC¼American Joint Committe on cancer; UBD¼ubiquitin D. *Po0.05 indicates a significant association between variables.
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for three groups. For categorical variables, data are expressed as
the numerical count and percentage and compared using the
Fisher’s exact test. McNemar’s and Wilcoxon signed rank tests
were used to compare the dependent categorical (UBD staining
for the 66 matched specimens in lymph node metastasis
(LNM) and primary tumour) and continuous (real-time PCR
analysis of UBD in 30 paired tumour tissues and adjacent normal
mucosa) variables, respectively. Survival curves were calculated
using the Kaplan–Meier method. A log-rank test was used to
compare the survival curves. If the data violated the proportional
hazard assumption, the Breslow test was performed instead of
the log rank test. Cox proportional hazard models were used
to investigate the independent risk factors for death and lymph
nodes metastasis. Significant factors in univariate Cox propor-
tional hazard models were selected for the final multivariate
regression model using the forward conditional method.
All statistical analyses were set with a significance level of 0.05
and performed using SPSS 15.0 statistical software (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Upregulation of UBD expression in primary colon cancer
as compared with adjacent normal mucosa
Of the 30 randomly selected, paired cases used for evaluating UBD
mRNA and protein expression, 22 (73%) colon cancers showed at
least a two-fold increase in UBD mRNA level as compared with
that of the adjacent, non-cancerous tissue. This difference in UBD
mRNA expression was significant (Po0.001, Figure 1). Subsequent
RT-PCR and western blotting confirmed that both UBD mRNA
and protein levels were upregulated in cancerous tissues as
compared with adjacent normal mucosa (Supplementary Figure S1).
Association of UBD TMA immunohistochemical staining
with patient clinicopathological parameters
Of the 203 normal mucosa specimens on the paired TMA, 191
(94%) showed negative UBD expression, with weak staining in 6
(3%) cases and strong staining in 6 (3%) additional cases. In
contrast, UBD expression was obvious in the majority of colon
tumour specimens, with weak staining in 71 (35%) cases, strong
staining in 64 (31%) cases and negative staining in 68 (33%) cases.
UBD was predominantly localized in the cytoplasm of colonic
epithelial and tumour cells, with nuclear staining only rarely
observed (Figure 2).
Among the 18 stage IV cases, only one patient who had received
noncurative metastatic resection and who was excluded from the
survival analysis, showed negative UBD staining in the primary
tumour. Associations between clinicopathological factors and UBD
expression are summarized in Table 1. Increased UBD expression
was signicantly correlated with depth of tumour invasion (pT
stage), LNM (pN stage), distant metastasis (M stage,), histologic
grade (Figure 2B–E) and advanced American Joint Committe on
cancer (AJCC) stage. No correlations were found between UBD
expression and age, gender, tumour location or vascular invasion.
The paired colon tumour and normal mucosa TMA was also
stained for Ki-67 expression. The median Ki-67 staining percen-
tage in the colon series was 25% (range, 5–80%). The frequency of
Ki-67 immunopositivity was 79% (160/203). Ki-67-positive stain-
ing was signicantly associated with tumour pT stage and advanced
patient clinical stage (Table 1). Also, Ki-67-positive staining was
8
6
4
2
0
Normal mucosa Tumour tissue
Δ
C
t
Figure 1 Real-time PCR analysis of UBD mRNA expression in 30 paired
colon tumour samples and adjacent normal mucosa. For each sample, the
relative UBD mRNA level was normalized using b-actin expression. Data
are presented as the median (line) DCt value with boxed 25th and 75th
percentiles. The data range is represented by the upper and lower bars.
.Po0.001.
Figure 2 Immunohistochemical staining of Ubiquitin D (UBD) expression in normal tissue and colon cancer. (A, B) Negative UBD expression in normal
colonic epithelium (A) and well-differentiated tumour (B). (C) Weak, focal cytoplasmic UBD staining in a well-differentiated colon tumour. (D, E) Diffuse,
intense UBD staining in moderately (D) and poorly (E) differentiated colon tumours. (F) Strong UBD staining in a colon cancer lymph node metastasis.
Original magnication  100.
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smore frequent in cases with weak and strong UBD staining than
with cases with negative UBD staining (37% weak vs 35% strong
vs 27% negative; P¼0.001), suggesting a statistical correlation
between UBD expression and Ki-67. Indeed, a co-expression
pattern between UBD and Ki-67 staining was often observed in the
same area of tumour tissues (Supplementary Figure S2).
It is worth noting that strong UBD staining was observed in
metastatic colon cancer cells within positive lymph nodes
(Figure 2F). In the 66 matched specimens available for analysis,
the rate of positive UBD expression in colon cancer lymph node
metastatic cells was higher than in the paired primary tumours
(55/66, 83% vs 46/66, 69%; P¼0.002, Table 2). These data suggest
that upregulated UBD expression may correlate with colon tumour
metastasis.
A total of 78 of the 195 (40%) patients who underwent curative
operations experienced disease relapse. There were 56 patients
(56/78, 71%) with recurrent disease within 36 months of surgery
(median 28 months, range 4–65 months). In this cohort, there was
an obviously signicant correlation between UBD expression and
total tumour recurrence. Patients with weak and strong UBD
staining in primary tumours had higher recurrent rates than did
patients with negative primary tumour staining (weak 38/68, 55%;
strong 26/60, 43%; negative 14/67, 20%; P¼0.006). Positive (weak
and strong) UBD expression was strongly associated with an
increased risk of tumour recurrence as compared with negative
UBD expression (RR 3.786; 95% CI 1.912–7.497; Po0.001).
However, there was no significant relationship detected between
UBD level of expression and time to onset of recurrent disease
(negative, range 6–65 months; weak, 4–58 months; strong, 5–64
months; P¼0.056).
Survival analysis and prognostic significance of UBD
expression according to AJCC stage stratification
To avoid the potential confounding influences of unresectable
metastatic tumours and additional patient post-operative manage-
ment on the results of these analyses, eight of the patients
with stage IV disease and noncurative surgery were excluded
from the survival analyses. At the end of the study, 66 of 195 (33%)
patients had died from their disease and 129 patients were
still alive. Patients with negative tumour UBD expression had
a better 5-year disease-free survival (DFS) and overall survival
(OS) rate than did the group with positive UBD expression (DFS:
83% negative vs 57% positive; OS: 85% vs 63%; P¼0.001,
respectively). Kaplan–Meier curves showed that the rate of
recurrence was signicantly elevated with positive UBD expression
(Figure 3). The mean relapse-free survival times for patients with
negative and positive UBD expression were 77.90±2.98 and
60.22±2.85 months, respectively (P¼0.001). The OS rate was
also signicantly decreased with increasing UBD expression
(Figure 3). By univariate analysis (Table 3), both increased post-
operative recurrence and decreased OS were associated with
pT stage, pN stage, AJCC stage, vascular invasion, Ki-67 expression
and UBD expression. Multivariate analysis (Table 3) demonstrated
that positive tumour UBD expression remained a signicant inde-
pendent prognostic factor for increased disease recurrence and
decreased survival.
To further define increased UBD expression as an independent
factor influencing tumour recurrence irrespective of clinical
disease stage, an analysis was performed with adjustment for
AJCC stage stratification. No significant difference was found
in DFS between the negative and positive UBD expression groups
of patients with stage I disease (Supplementary Figure S3A).
Two patients with negative UBD staining died, which may need
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Figure 3 Kaplan–Meier plots of disease-free survival (left) and overall survival (right) of patients with colon cancer who underwent curative resections on
the basis of the immunohistochemical UBD expression.
Table 2 UBD immunohistochemical staining for protein expression in
matched primary colon cancer and lymph node metastases
Lymph node
Primary colon cancer
metastases Negative Weak Strong Total P-value
Negative 4 (6.%)
a 5 (7.56%) 2 (3.%) 11 (16.7%) 0.002
b
Weak 1 (1.5%) 3 (4.5%) 8 (12.1%) 12 (18.2%)
Strong 15 (22.7%) 15 (22.7%) 13 (19.7%) 43 (65.2%)
Total 20 (30.3%) 23 (34.9%) 23 (34.8%) 66 (100.%)
an (%).
bSignificant difference in protein expression by McNemar’s test.
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set. However, significant differences in DFS were detected
in patients with stage II and III disease. The 5-year DFS rates
in stage II patients of negative and positive UBD expression
were 100 and 77.3%, respectively (Supplementary Figure S3B),
and in stage III were 64 and 38%, respectively (Supplementary
Figure S3C). Of the 10 patients with stage IV disease and positive
tumour UBD staining, all experienced tumour recurrence within
3 years after radical resection. These data indicate that UBD levels
are with a shorter relapse-free duration that was independent of
tumour staging.
DISCUSSION
This is the first report showing the association of upregulated
human colon cancer UBD expression with cancer progression and
recurrence independent of Pathological Tumour-Node-Metastasis
staging. These data support UBD as a novel prognostic indicator of
colon cancer outcomes, in particular for forecasting recurrence in
patients with stage II and III disease following curative surgery.
Correlations of UBD expression with cell proliferation and
advancing tumour stages suggests that UBD may contribute to
the progression of colon carcinogenesis.
Table 3 Univariate and multivariate Cox proportional hazard models for overall survival and disease-free survival
Overall survival Disease-free survival
Univariate Multivariate Univariate Multivariate
HR (95% CI) P* HR (95% CI) P* HR (95% CI) P* HR (95% CI) P*
Age 1.00 (0.98,1.02) 0.834 1.00 (0.98, 1.02) 0.952
Gender
Male — —
Female 1.19 (0.72,1.94) 0.500 1.14 (0.72, 1.78) 0.581
Tumour location
Right — —
Transverse 0.80 (0.30,2.09) 0.643 0.83 (0.34, 1.98) 0.669
Left 1.19 (0.71,1.99) 0.505 1.12 (0.70, 1.79) 0.631
T stage
T1 0.40 (0.10, 1.65) 0.205 0.40 (0.09, 1.80) 0.235 0.34 (0.08, 1.39) 0.132 0.34 (0.08, 1.45) 0.144
T2 0.12 (0.03, 0.49) 0.003 0.32 (0.07, 1.40) 0.131 0.16 (0.05, 0.52) 0.002 0.44 (0.13, 1.53) 0.197
T3 0.36 (0.20, 0.63) o0.001 0.34 (0.19, 0.61) o0.001 0.42 (0.26, 0.70) 0.001 0.41 (0.25, 0.70) 0.001
T4 — — — —
N stage
N0 — — —
N1 3.74 (1.96,7.12) o0.001 2.85 (1.43, 5.68) 0.003 2.73 (1.57, 4.73) o0.001 1.97 (1.10, 3.52) 0.022
N2 15.02 (7.85,28.75) o0.001 9.65 (4.60, 20.25) o0.001 10.22 (5.78, 18.08) o0.001 6.89 (3.60, 13.17) o0.001
M stage
M0 — — — —
M1 14.74 (8.15, 26.67) o0.001 4.74 (2.00, 11.26) o0.001 9.93 (4.91, 20.07) o0.001 4.94 (2.29, 10.67) o0.001
AJCC stage
I— — — —
II 2.08 (0.47,9.20) 0.336 2.07 (0.61, 6.96) 0.241
III 9.59 (2.31,39.78) 0.002 6.69 (2.07, 21.58) 0.001
IV 48.10 (10.15,228.07) o0.001 37.18 (9.95, 138.97) o0.001
Differentiation
High — — — —
Moderate 2.37 (1.34, 4.18) 0.003 1.24 (0.65, 2.36) 0.514 2.26 (1.35, 3.79) 0.002
Low 7.50 (4.11, 13.68) o0.001 2.28 (1.06, 4.88) 0.034 4.87 (2.64, 8.97) o0.001
Vascular invasion
No — —
Yes 5.22 (2.76,9.86) o0.001 4.12 (2.16, 7.86) o0.001
UBD
Negative — — — —
Weak 2.62 (1.33,5.15) 0.005 1.33 (0.63, 2.81) 0.453 3.28 (1.78, 6.06) o0.001 1.82 (0.94, 3.53) 0.075
Strong 3.21 (1.62,6.37) 0.001 2.31 (1.08, 4.93) 0.030 2.64 (1.38, 5.07) 0.003 2.03 (1.03, 3.98) 0.041
Ki-67
Negative — —
Positive 2.17 (1.07,4.38) 0.032 2.06 (1.09, 3.89) 0.027 1.88 (0.96, 3.69) 0.065
Abbreviations: AJCC¼American Joint Committe on cancer; CI¼confidence interval; HR¼Hazard ratio; UBD¼ubiquitin D. *Po0.05 indicated that the 95% CI of HR was not
including 1.
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first found during mapping of the HLA-F gene (Fan et al, 1996).
Upregulation of UBD mRNA has been observed in hepatocellular,
gastrointestinal and gynecological carcinomas (Lee et al, 2003) and
expression of both UBD mRNA and protein has been verified in
fibroblasts and hepatic cancer cells (Raasi et al, 2001; Lukasiak
et al, 2008a). In the present study, we first measured UBD
expression in fresh frozen specimens of colon cancer and found
that UBD mRNA and protein expression levels were higher in
colon tumour tissue than in the surrounding noncancerous
mucosa. These data indicated that UBD was upregulated at both
transcriptional and post-transcriptional levels. Further validation
by immunohistochemistry showed that 66% (135/203) of primary
colon cancers had positive UBD protein staining, whereas only 6%
(12/203) of normal colonic epithelium were immunoreactive for
UBD. These data suggest that UBD might have an important role in
the progression of colon carcinogenesis. UBD is reported to have
important roles in the regulation of cell mitosis, chromosome
instability, apoptosis and immune response (Raasi et al, 2001;
Canaan et al, 2006; Lim et al, 2006; Ren et al, 2006).
UBD was reported to be localized in the nuclei of hepatocellular
and gastric cancer cells, indicating that it might mediate
transcriptional control and tumour development (Lee et al, 2003;
Ji et al, 2009). However, in the present study, nuclear localization
of UBD was only rarely observed. It has been reported that UBD
was closely related to gastric cancer LNM and advanced tumour
node metastasis stages (Ji et al, 2009). However, there are currently
no published reports on the possible association of UBD
expression with the clinicopathological features of colon cancer.
Our results revealed significant correlations between tumour UBD
overexpression and clinical stage, pT, pN stage, distant metastasis
and tumour histological grade. These strong correlations suggest
that UBD overexpression might promote tumour invasion and
metastasis, and that UBD could possibly be used a biomarker for
identification of subsets of colon cancer with a more aggressive
phenotype. Our data also showed a significant association between
tumour UBD expression and Ki67 index, suggesting that UBD may
be involved in the increased proliferation of colon cancer cells.
It has been suggested that UBD expression may be related to
other biomarkers used to predict tumour metastasis, such as
CD44v6, nm23, MTA1 and matrix metalloproteases (Ji et al, 2009).
Our data revealed that UBD levels were higher in tumours with
associated LNM than those without LNM. Positive UBD protein
expression was signicantly higher in metastatic colon cancer cells
within lymph nodes than in matched primary tumours. These data
suggested that increased UBD expression might correlate with the
invasive behavior and metastatic processes of colon cancer.
The mechanism by which UBD contributes to tumorigenesis is
not well elucidated. According to previous reports, UBD is a
downstream target of p53 and its promoter is negatively regulated
by p53. UBD overexpression in cancers was ascribed to transcrip-
tional upregulation upon the loss of p53 (Zhang et al, 2006), but
mutations in the UBD coding sequence have not been reported
(Lukasiak et al, 2008b). The proinammatory cytokines interferon-g
and TNF-a can induce UBD expression in conjunction with an
immune response within the tumour microenvironment (Lukasiak
et al, 2008b). Excessive UBD protein might bind noncovalently to
spindle-assembly checkpoint protein MAD2 (Liu et al, 1999; Mapelli
et al, 2007), resulting in the inhibition of MAD2 function during the
prometaphase stage of the cell cycle and a reduction in cell-cycle
time (Lim et al, 2006). These changes could lead to genomic
instability and tumour formation (Michel et al, 2001; Ren et al,
2006; Adler et al, 2009). In addition, UBD may influence caspase-
dependent apoptosis in HeLa and human renal tubular epithelial
cells (Raasi et al, 2001; Ross et al, 2006). Further experimentation is
required to define the molecular mechanisms governing the
potential role UBD expression in colon cancer progression.
Until now, valid prognostic biomarkers for colon cancer have not
been established (Grady and Carethers, 2008). In the present study,
patients with a high tumour UBD expression had an increased risk of
tumour recurrence and shorter survival. It is interesting that the
patients of stage II and III disease and tumours with positive UBD
expression were at greater risk for tumour recurrence. The 5-year
DFS rates for the negative and positive UBD expression groups were
93 and 80%, respectively, for stage II disease and 70.8 and 36%,
respectively, for stage III disease. Although all 10 patients with stage
IV disease who were included in the survival analysis had positive
tumour UBD expression and post-operative disease recurrence, a
statistical relationship could not be established owing to the small
sample size. Although lymph node status is different between stage II
and III disease and LNM is usually regarded as a poor prognosis
factor for colon cancer, whether lymph node involvement should be
routinely assessed remains a topic for debate (Johnson et al, 2006;
Wang et al, 2008). Also, the current AJCC classification of stage III
represents a heterogeneous patient population (Johnson et al, 2006).
The present study has delineated the potential utility of assessing
UBD expression for predicting recurrence of stage III (lymph node-
positive) patients. This information could contribute to clinical
decisions and help target drastic therapeutics to patient subgroups
with a higher likelihood of disease recurrence and metastasis. Study
limitations include the small number of patients with relatively short
follow-up time. As increased UBD expression in tumour cells is a
phenotypic change that indicates a preneoplastic change, it will be
interesting to include colon adenomas with or with out dysplasia or
intra mucosal carcinoma in future studies to validate our results
showing that increased UBD expression in colon cells may indicate a
preneoplastic change.
To the best of our knowledge, this is the first report to show
the clinical signicance of tumour UBD expression in colon cancer.
UBD was overexpressed in tumour tissue and was associated with
aggressive colon cancer phenotypes. We propose that tumour UBD
expression may be a clinically useful, prognostic indicator of poor
patient survival, independent of tumour stage. Overexpression of
UBD in stage II and III colon cancer may correlate with disease
recurrence. These preliminary findings need to be verified in
a larger, prospective, controlled clinical study.
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sAppendix
Statement of translational relevance
This is the first report on ubiquitin D association with human
colon cancer progression and tumour recurrence independent
of Pathological Tumour-Node-Metastasis staging. Although
lymph node metastasis and advanced Pathological Tumour-
Node-Metastasis stage are widely accepted prognostic indicators
for colon cancer (O’Connell et al, 2004), methods for assessing
lymph node involvement and heterogeneity within tumour
classifications remain controversies (Johnson et al, 2006; Wang
et al, 2008). Ubiquitin D was found to predict tumour recurrence
in patients with lymph node-negative cancer (stage II), for whom
post-operative chemotherapy is only recommended on the
basis of the clinical parameters, as there are currently no validated
tissue-based biomarkers of disease recurrence. These findings
could be clinically translated to help to select patient sub-groups with
higher metastatic potential and offer them more appropriate
interventions. A major study limitation is the small number of
patients with relatively short follow-up time. Larger, prospective
controlled studies are required to confirm the present results.
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